These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior and histology. Imai H; Nakamura T; Endo K; Narabayashi H Brain Res; 1988 Dec; 474(2):327-32. PubMed ID: 3264746 [TBL] [Abstract][Full Text] [Related]
6. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Clarke CE; Sambrook MA; Mitchell IJ; Crossman AR J Neurol Sci; 1987 May; 78(3):273-80. PubMed ID: 3495642 [TBL] [Abstract][Full Text] [Related]
7. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Bankiewicz KS; Oldfield EH; Chiueh CC; Doppman JL; Jacobowitz DM; Kopin IJ Life Sci; 1986 Jul; 39(1):7-16. PubMed ID: 3487691 [TBL] [Abstract][Full Text] [Related]
8. MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. Crossman AR; Clarke CE; Boyce S; Robertson RG; Sambrook MA Can J Neurol Sci; 1987 Aug; 14(3 Suppl):428-35. PubMed ID: 3119180 [TBL] [Abstract][Full Text] [Related]
9. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Yoshimura N; Mizuta E; Kuno S; Sasa M; Yoshida O Neuropharmacology; 1993 Apr; 32(4):315-21. PubMed ID: 8098860 [TBL] [Abstract][Full Text] [Related]
10. A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys. Wolters EC; Kebabian JC; Guttman M; Mak E; Pate BD; Calne DB Neurosci Lett; 1988 Dec; 95(1-3):257-61. PubMed ID: 3265771 [TBL] [Abstract][Full Text] [Related]
11. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. Falardeau P; Bouchard S; Bédard PJ; Boucher R; Di Paolo T Eur J Pharmacol; 1988 May; 150(1-2):59-66. PubMed ID: 3261249 [TBL] [Abstract][Full Text] [Related]
12. Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism. Klintenberg R; Svenningsson P; Gunne L; Andrén PE J Neural Transm (Vienna); 2002 Oct; 109(10):1295-307. PubMed ID: 12373562 [TBL] [Abstract][Full Text] [Related]
13. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Bédard PJ; Di Paolo T; Falardeau P; Boucher R Brain Res; 1986 Aug; 379(2):294-9. PubMed ID: 3488796 [TBL] [Abstract][Full Text] [Related]
14. Antiparkinsonian effects of BAM-1110, a novel ergoline derivative, in MPTP-treated cynomolgus monkeys. Kuno S; Mizuta E; Sakamoto H; Ichihara K; Nagasaka M Clin Neuropharmacol; 1998; 21(1):35-40. PubMed ID: 9579283 [TBL] [Abstract][Full Text] [Related]
15. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys. Grondin R; Bédard PJ; Britton DR; Shiosaki K Neurology; 1997 Aug; 49(2):421-6. PubMed ID: 9270571 [TBL] [Abstract][Full Text] [Related]
16. Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey. Page RD; Sambrook MA; Crossman AR Neuroscience; 1993 Jul; 55(1):147-65. PubMed ID: 7688878 [TBL] [Abstract][Full Text] [Related]
17. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Schneider JS Pharmacol Biochem Behav; 1989 Sep; 34(1):193-6. PubMed ID: 2576311 [TBL] [Abstract][Full Text] [Related]
18. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409 [TBL] [Abstract][Full Text] [Related]
19. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Mitchell IJ; Boyce S; Sambrook MA; Crossman AR Brain; 1992 Jun; 115 ( Pt 3)():809-24. PubMed ID: 1628204 [TBL] [Abstract][Full Text] [Related]
20. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Graham WC; Sambrook MA; Crossman AR Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]